Vascepa icosapent ethyl: Phase III ongoing

An IDMC recommended continuation of the double-blind, placebo-controlled, international Phase III REDUCE-IT trial comparing Vascepa plus a statin vs. a statin alone in 8,175 patients with elevated tri...